MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion

YU-JIANG LIU1, WEI LI1, FENG CHANG1, JIAN-NA LIU1, JUN-XIN LIN2 and DE-XI CHEN1

1Department of Spine Surgery, Hiser Medical Center of Qingdao; 2Department of Orthopedics, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong 266000, P.R. China

Received June 2, 2017; Accepted November 23, 2017

DOl: 10.3892/or.2017.6142

Abstract. Recent studies have demonstrated that microRNAs (miRNAs/miRs) are involved in osteosarcoma tumorigenesis, progression, invasion and metastasis. For example, miR-505 plays important roles in human carcinogenesis; however, its exact function in osteosarcoma remains unclear. MicroRNA profiles of osteosarcoma and normal tissues were obtained by miRNA microarray assays, which were validated by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Then, high-mobility group box 1 (HMGB1) expression was evaluated by qRT-PCR and western blot analysis. The correlation between miR-505 and HMGB1 was analyzed by Pearson correlation. In vitro, the biological functions of miR-505 were examined by wound healing, MTT and Transwell assays and western blot analysis in MG63 cells transfected with miRNA mimics or empty vector. Luciferase assay was utilized to assess whether HMGB1 is a target of miR-505. miRNA microarrays revealed 26 aberrant miRNAs in osteosarcoma tissues; miR-505 showed the most pronounced decrease (P<0.01), which was significantly associated with TNM stage and metastasis status (P<0.05). In addition, HMGB1 was highly expressed in osteosarcoma tissues (P<0.01), with a significantly negative correlation with miR-505 (r=-0.6679, P<0.001). Furthermore, miR-505 inhibited proliferation, migration and invasion abilities of MG63 cells (P<0.01). Moreover, luciferase activity of the HMGB1-3'-UTR plasmid was suppressed following miR-505 binding (P<0.01). Finally, HMGB1 overexpression partly reversed the effects of miR-505 on MG63 cells. In conclusion, miR-505 levels are decreased in osteosarcoma tissues, and reduced miR-505 expression is significantly associated with poorer clinical prognosis in patients with osteosarcomas. miR-505 inhibits osteosarcoma cell proliferation, migration and invasion by regulating HMGB1.

Introduction

Primary bone cancers are extremely rare neoplasms, accounting for less than 0.2% of all cancers. In 2015, 2,970 patients were newly diagnosed with bone and joint cancer in the United States, with 1,490 deaths from the disease (1). Osteosarcoma is the most common primary malignant bone tumor in children and young adults. The median age of patients with osteosarcoma is 20 years (2). Patients always seek medical attention following symptoms of pain and swelling. Unfortunately, approximately 10-20% of cases present with metastatic disease at diagnosis (3). What is more, ~30% of patients with localized disease and 80% of those presenting with metastatic disease will experience relapse (4). Thus, it is critical to develop new strategies to treat recurrent and/or metastatic osteosarcomas.

Recently, several studies have focused on the impact of microRNAs (miRNAs/miRs) on tumor initiation and progression. miRNAs are short non-coding RNAs that regulate the expression of target mRNAs by binding to their 3’ untranslated regions (UTRs), causing degradation or translation inhibition (5,6). Indeed, specific miRNAs contribute to tumor growth, progression, metastasis and drug resistance in osteosarcoma (7-10). For example, miR-505 was reported to be involved in many cancer types (11-13); however, its exact role in osteosarcoma remains unknown. The present study, therefore, aimed to assess the role of miR-505 in osteosarcoma, exploring its biological functions in osteosarcoma cells.

Direct targets of miR-505 were searched for at microRNA.org and using Diana Tools, and high miTG (0.982) and mirSVR (-2.98) scores were found for high mobility group box 1 (HMGB1). HMGB1 is a transcription factor that outside the cell acts as a potent pro-inflammatory cytokine in the immune response (14). It was also found in culture supernatants of numerous osteoblast preparations as well as isolated osteoclast precursors and osteoclasts (15). HMGB1 expression is associated with cancer development by interfering with several signaling pathways (16). Thus, we hypothesized HMGB1 to be a candidate target of miR-505, and assessed whether this miR could modulate HMGB1 expression in osteosarcoma cells.

Correspondence to: Dr Jun-Xin Lin, Department of Orthopedics, Qilu Hospital of Shandong University (Qingdao), 758 Hefei Road, North, Qingdao, Shandong 266000, P.R. China E-mail: junxin_l07@163.com

Abbreviations: miRNAs, microRNAs, HMGB1, high mobility group box 1; qRT-PCR, quantitative real-time polymerase chain reaction

Key words: osteosarcoma, miR-505, prognosis, invasion, HMGB1
In the present study, miRNA expression profiles in osteosarcoma and adjacent normal tissue specimens were compared, and a subset of deregulated miRNAs were identified. Specifically, miR-505 was revealed as a candidate oncogenic miRNA in osteosarcoma, showing a significant decrease. Further experiments demonstrated that the reduced miR-505 level is associated with poorer clinical prognosis in patients with osteosarcomas. In addition, miR-505 overexpression resulted in reduced cell growth, migration and invasion. More importantly, HMGBI was confirmed as a direct target gene for miR-505 in osteosarcoma.

Materials and methods

Patients and tissue specimens. A total of 37 freshly frozen osteosarcoma tumor and adjacent normal tissue specimens were obtained by resection or biopsy from 2013 to 2014 at the Department of Orthopedics, Qilu Hospital of Shandong University. None of the patients had received any treatment prior to surgery. All specimens were snap-frozen in liquid nitrogen within 2 h and stored at -80°C for further analysis. Inclusion criteria were: diagnosis as osteosarcoma confirmed by light microscopy and immunohistochemistry; complete clinical and pathological data available. Exclusion criteria were: family history of cancer; other chronic systemic disease; unwillingness to participate in the present study. Written informed consent was provided by all patients. The study was approved by the Ethics Committee of Qilu Hospital of Shandong University.

MicroRNA microarray and RT-PCR. A total of 5 paired tumor and adjacent normal tissue specimens were randomly selected. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and miRNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Samples with RNA integrity number (RIN) >8 were processed for hybridization. Total RNA was labeled using the miRCURY™ Array Power labeling kit (Exiqon, Copenhagen, Denmark) and hybridized to the microRNA microarray using miRCURY™ LNA Array (Exiqon). Scanned images were then imported into the GeenPix 4000B software (Axon Instruments, Sunnyvale, CA, USA). The SpotData Pro software was used for data analysis. Hierarchical clustering was performed using Data Matching Software.

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate microarray data. First strand cDNA was synthesized using TaqMan MicroRNA Reverse Transcription kit with the stem-loop RT primer. Amplification was performed using Power SYBR-Green PCR Master Mix in triplicate, on Roche LightCycler 480 Real-Time PCR System with the following conditions: 2 min of initial denaturation at 95°C, and 40 cycles at 94°C (15 sec), 60°C (60 sec) and 72°C (30 sec). Relative miRNA and mRNA expression levels were determined using the 2^ΔΔCt method and normalized to U6. To assess HMGBI mRNA levels, qRT-PCR was performed with SYBR-Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions; GAPDH was used as an endogenous control. The primers used for qRT-PCR are shown in Table I.

Cell culture and treatment. The human osteosarcoma cell lines U2-OS, MG63, HOS and SAOS-2, as well as the normal osteoblastic cell line hFOB 1.19 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). hFOB 1.19 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F-12 (1:1; Invitrogen) and osteosarcoma cells in osteoblast growth medium (Invitrogen). All cells were maintained at 37°C in a humidified incubator with 5% CO2 in media supplemented with 10% fetal bovine serum (FBS; Invitrogen), 1% of 100 U/ml penicillin and streptomycin (Invitrogen) and 2 mM glutamine. The miR-505 mimic and mimics negative control (miR-NC) were obtained from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). Cells were transfected with 30 nM miR-505 mimics or miR-NC using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Overexpression of HMGBI was achieved using the pcDNA3.1/HMGBI transfection and the pcDNA3.1/CAT (vector) was used as its negative control.

MTT assay. Cells (1x10^4/well) were seeded into 96-well plates and incubated for 24, 48, 72 and 96 h, respectively. Then, 20 µl of 5 mg/ml MTT reagent (Sigma-Aldrich, St. Louis, MO, USA) in phosphate-buffered saline (PBS) was added to each well and incubated for 4 h. Subsequently, 150 µl of dimethyl sulfoxide (DMSO; Sigma-Aldrich) was added to dissolve the precipitates. Absorbance was measured at 450 nm on a microplate reader (Multiskan; Thermo Fisher Scientific, Waltham, MA, USA). A growth curve was generated with time and absorbance on the horizontal and vertical axes, respectively.

Cell migration assay. MG63 cells were transfected with miR-505 mimics or miR-NC as well as pcDNA3.1/HMGBI or pcDNA3.1/CAT, following the manufacturer's instructions. After transfection, a sterile pipette tip was used to scratch the cell layer at ~90% confluency. After washing with PBS three times, the cells were further incubated at 37°C for 24 h. Micrographs were acquired on an inverted microscope at 0 and 24 h, respectively, after wounding.

Invasion assay. Transfected cells were seeded onto Transwell 24-well plates coated with diluted Matrigel, with serum-free media containing 5% FBS used as a chemotactant. After 24 h of incubation, the medium was removed, and chambers were washed twice with PBS. The cells on the upper side of the inserts were softly scraped; those migrated to the lower surface were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Microphotographs were obtained on an immunofluorescence microscope (Olympus BX53; Olympus, Tokyo, Japan) at x200 magnification.

Western blot analysis. Total protein was extracted from cells with 1% RIPA lysis buffer (Beyotime Institute of Biotechnology, Haimen, China); protein quantitation was carried out by the BCA method. Equal amounts of protein (30 µg) were separated by SDS-PAGE and transferred onto PVDF membranes. After blocking, the samples were incubated with relevant antibodies, including anti-HMGBI (cat. no. ab79823, 1:1,000; Abcam, Cambridge, MA, USA), anti-MMP2 (cat. no. 40994, 1:1,000; Cell Signaling Technology, Danvers, MA, USA), anti-MMP9 (cat. no. 13667, 1:1,000; Cell Signaling Technology) anti-cyclin D1 (1 µg/ml; cat. no. AF4196; R&D Systems, Minneapolis, MN, USA), and anti-cyclin D1 (1 µg/ml; cat. no. AF4196; R&D Systems, Minneapolis, MN, USA).
Table 1. The TaqMan stem-loop primers for reverse transcription PCR and the forward and reverse primers for real-time PCR.

| Accession      | ID       | Sequence                      | TaqMan primer | PCR-F        | PCR-R         |
|----------------|----------|-------------------------------|----------------|--------------|--------------|
| MIMAT0000267   | hsa-miR-210 | CUGUGCUGUGUGACACGGGCGAUGA    | GTCGTATCCAGTGCGTGCTGGAGTGGGCAATTGCAGTGGATACGACTCAGCC | CTGGTGCGTGACAGC | |
| MIMAT0000758   | hsa-miR-135b | UAUGGCUUUUUAUCCUAUGUGA       | GTCGTATCCAGTGCGTGCTGGAGTGGGCAATTGCAGTGGATACGACTCAGCAT | TATGGCTTGCATTCT | |
| MIMAT0002876   | hsa-miR-505   | CGUCAACACUUGUCUGUUUCCU        | GTCGTATCCAGTGCGTGCTGGAGTGGGCAATTGCAGTGGATACGACAGGAA   | CGTCAACACTTGCTGG  | |
| MIMAT000069    | hsa-miR-16    | UAGCAGCAGCAUAAAUAUGGCG        | GTCGTATCCAGTGCGTGCTGGAGTGGGCAATTGCAGTGGATACGACAGGCAA | GGGTAGCAGCAGCAGAAATAT | |
| U6             | PCR-F     | GCTCGTCTGGCAGCACA           |               |              |              |
| U6             | PCR-R     | AACGCTTCAGAATTGCGT           |               |              |              |
| GAPDH          | PCR-F     | ACCCAGAAGACTGTGGAGTG         |               |              |              |
| GAPDH          | PCR-R     | CAGTGAGCTCCCAGGTTCAG        |               |              |              |
| HMGB1          | PCR-F     | CTTCTTGAGGGGAAGCTAGT         |               |              |              |
| HMGB1          | PCR-R     | TTTGGATGGTGCTAGTATTG         |               |              |              |
USA) and anti-GAPDH (cat. no. GTX100118, 1:5,000; GeneTex, Inc., Irvine, CA, USA), overnight at 4°C. This was followed by incubation with HRP-labeled goat anti-rabbit or anti-rat IgG (H+L) (1:5,000; Beyotime Institute of Biotechnology) for 60 min at room temperature. Immunodetection was performed by enhanced chemiluminescence (ECL Plus kit; Beyotime Institute of Biotechnology) and visualized on a G:Box Chemi imaging system (Syngene, Cambridge, UK).

Luciferase reporter assay. The 3'-UTR fragment of HMGB1, predicted to be the miRNA binding site, was synthesized and inserted into the XbaI and FseI sites of the pGL3 control vector (Promega, Madison, WI, USA) to generate a HMGB1-Wt luciferase reporter. Mutation of the binding site was introduced by site-directed mutagenesis (Promega), to yield Mut. For luciferase reporter assay, MG63 cells were cultured in 96-well plates and co-transfected with miR-505 mimics (or negative control) using Lipofectamine 2000. After transfection for 48 h, cells were harvested, and luciferase activity was assayed with the luciferase reporter assay system (Promega).

Statistical analysis. All experiments were performed in triplicate, with values expressed as mean ± standard deviation (SD). Group comparison was carried out by unpaired two-tailed Student's t-test with the SPSS 19.0 software. P<0.05 was considered statistically significant.

Results

miR-505 is specifically downregulated in osteosarcoma tissues. To obtain microRNA expression patterns, 5 paired osteosarcoma tissue samples were randomly selected, and their miRNA expression profiles were determined by microRNA microarray. Notably, among the unique 2,150 human miRNA probes, 26 were differentially expressed between the osteosarcoma and adjacent normal tissues; among these, 12 were markedly upregulated and 14 downregulated (Fig. 1 and Table II). miR-505 showed the most pronounced decrease. To confirm the microarray findings, 4 significantly altered miRNAs (the most significantly dysregulated miRNAs),
including miR-210, miR-135b, miR-505 and miR-16, were assessed by quantitative real-time reverse transcription-PCR (qRT-PCR). Their expression levels were evaluated in 37 paired tissue samples. As shown in Fig. 2, after normalization to U6, the expression trends of the 4 miRNAs were consistent with the microarray findings. However, the fold changes of expression differed somewhat between both assays.

**Associations of miR-505 expression with clinicopathological features in osteosarcoma.** To assess the clinical value of miR-505 in osteosarcoma, clinical characteristics of the enrolled patients were collected by an Orthopedist. Then, patients were divided into groups according to various clinicopathological features (Table III). miR-505 expression was used to divide the patients into two groups according to its median value of 1.85. Notably, significant associations of miR-505 expression with TNM stage and metastasis were obtained (P=0.005 and 0.036, respectively). However, no significant associations of miR-505 expression with age, sex, histologic type, tumor size and nuclear grade were observed.

### Table II. Differentially expressed miRNAs between osteosarcoma tissues and corresponding normal tissues.

| miRNA expression profiles | Upregulated miRNAs | Downregulated miRNAs |
|--------------------------|--------------------|-----------------------|
| miRNA name               | Fold change        | P-values              | miRNA name               | Fold change        | P-values              |
| hsa-miR-210              | 6.21               | 0.0035                | hsa-miR-505              | 7.36               | 0.0101                |
| hsa-miR-135b             | 6.06               | 0.0306                | hsa-miR-16               | 7.11               | 0.0232                |
| hsa-miR-21               | 5.91               | 0.0121                | hsa-miR-29a              | 6.34               | 0.0180                |
| hsa-let-7c               | 5.42               | 0.0263                | hsa-miR-29b              | 6.21               | 0.0316                |
| hsa-miR-93               | 5.04               | 0.0076                | hsa-miR-153-5p           | 5.73               | 0.0246                |
| hsa-miR-155              | 4.60               | 0.0402                | hsa-miR-31               | 5.13               | 0.0023                |
| hsa-miR-150              | 4.31               | 0.0131                | hsa-miR-34a              | 4.69               | 0.0130                |
| hsa-miR-542-5p           | 4.03               | 0.0169                | hsa-miR-34b              | 4.24               | 0.0302                |
| hsa-miR-652              | 3.39               | 0.0114                | hsa-miR-203              | 3.84               | 0.0173                |
| hsa-miR-183              | 3.23               | 0.0027                | hsa-miR-125              | 3.37               | 0.0218                |
| hsa-miR-211              | 2.65               | 0.0126                | hsa-miR-132              | 2.93               | 0.0104                |
| hsa-miR-519              | 2.07               | 0.0105                | hsa-miR-206              | 2.67               | 0.0023                |
| hsa-miR-505              | 7.36               | 0.0101                | hsa-miR-424              | 2.31               | 0.0010                |
| hsa-miR-91               | 2.01               | 0.0156                | hsa-miR-91               | 2.01               | 0.0156                |

Figure 3. An inverse correlation between HMGB1 mRNA and miR-505 expression in osteosarcoma tissues. (A) The expression of HMGB1 was significantly increased in osteosarcoma tissues, compared with that in the adjacent normal tissues (**P<0.01). (B) Pearson correlation was used to analyze the relationship between miR-505 and HMGB1 mRNA in osteosarcoma tissues. (C and D) Western blot analysis shows the expression of HMGB1 protein in osteosarcoma tissues and adjacent normal tissues.
These findings suggested that decreased miR-505 expression was significantly associated with poorer clinical prognosis in patients with osteosarcoma.

**HMGB1 is highly expressed in osteosarcoma tissues.** The important role of miR-505 in osteosarcoma prompted us to explore the probable molecular mechanisms. As miRNAs always perform their functions by binding the 3'UTRs of target mRNAs, several target prediction software programs, including TargetScan, miRDB, and miRBase, were used to identify direct targets of miR-505. HMGB1 was revealed as a candidate, and has been reported to be overexpressed in several cancers and
miR-505 directly downregulates HMGB1 in osteosarcoma cells. Since HMGB1 was found to be negatively correlated with miR-505 in osteosarcoma tissues, further experiments were performed to validate the interaction of miR-505 with HMGB1. As shown in Fig. 5A, the complementary sequence of miR-505 was present in the 3'-UTR of HMGB1 mRNA; a mutant was generated as underlined in the sequence. Then, HMGB1 expression was assessed in the miR-505 mimics, miR-NC and control groups by western blot analysis in U2-OS and MG63 cells. Notably, lower HMGB1 protein levels were found in the miR-505 mimic group (Fig. 5B; P<0.01). Next, HMGB1 mRNA amounts were detected by qRT-PCR in both cell lines, and HMGB1 was also downregulated with miR-505 overexpression (P<0.01) (Fig. 5C). Moreover, U2-OS and MG63 cells were transfected with miR-505 mimics or miR-NC, and luciferase reporter assay was performed to assess whether HMGB1 was an authentic target gene of miR-505. As shown in Fig. 5D, luciferase activity was significantly decreased in cells transfected with the HMGB1-WT-3'-UTR vector and miR-505 mimics, compared with that in cells transfected with control RNAs (P<0.01). Meanwhile, no significant change in relative luciferase activity was found when the miR-505 binding site was mutated. Taken together, these findings suggested that HMGB1 is a target of miR-505 in MG63 cells.

miR-505 inhibits proliferation, migration and invasion in osteosarcoma cells by negatively regulating HMGB1. Although HMGB1 as a direct target of miR-505 in MG63 cells was validated by the luciferase reporter assay, whether miR-505 inhibits MGB63 cell proliferation, migration and invasion through binding to HMGB1 remained unclear. Thus, a pcDNA3.1/HMGB1 was generated for HMGB1 overexpression. Relative HMGB1 protein amounts were detected in the different groups as shown in Fig. 6A. Notably, HMGB1 overexpression showed increased abilities of growth, migration and invasion (P<0.01), as shown in Fig. 6B-D. Cell viability-related protein levels also showed a certain degree of increase (Fig. 6E). Taken together, the above data strongly suggested that miR-505 induced MG63 cell proliferation, migration and invasion by downregulating HMGB1.

Discussion

Metastasis and recurrence are the leading causes of mortality in most patients with cancers, including osteosarcoma. The
optimal treatment strategy for such patients has yet to be defined. Although several clinical trials have reported that adjuvant chemotherapy is associated with improved outcomes in osteosarcoma patients, the prognosis of recurrent disease remains poor, with a long-term post-relapse survival of <20% (17-19). It is generally accepted that tumor cells acquiring migration and invasion abilities to depart from their original locations is the prerequisite for metastasis. Therefore, it is critical to identify effective agents which could significantly inhibit cell growth, migration and invasion of osteosarcoma cells.

miRNAs were firstly associated with cancer in 2002, initially with chronic lymphocytic leukemia (CLL) and subsequently with many other malignancies (20). Osaki et al (21) indicated that miR-143 was the most downregulated miRNA in human osteosarcoma cell lines in a mouse model, and demonstrated that systemic administration of miR-143 with atelocollagen into cancer model mice suppressed spontaneous lung metastasis of osteosarcoma. Similarly, another study evaluated 23 osteosarcoma tissue samples by microRNA microarrays, and found that miR-133a and miR-133b levels are significantly decreased. Overexpression of miR-133b in osteosarcoma cell lines obviously inhibits cell proliferation, invasion and migration (22). In addition, a recent study reported that relative expression levels of miR-99a and mTOR mRNA were found to be associated with advanced clinicopathological characteristics (advanced surgical stage, metastasis, recurrence and poor response to chemotherapy) in patients with osteosarcoma, with low miR-99a expression correlating with shorter overall and disease-free survival rates; in addition, miR-99a was found to be an independent prognostic factor of patients with osteosarcoma (23). We also performed a microarray to obtain the miRNA profile in osteosarcoma. A total of 26 miRNAs showed altered expression in osteosarcoma tissues in this study and we subsequently focused on miR-505, the most downregulated one among our findings. To the best of our knowledge, multiple studies have found that miR-505 inhibited cell proliferation by inducing apoptosis, and promoted chemoresistance in breast cancer (24,25). In addition, transfection with miR-505 mimics inhibited proliferation, and reduced tumorigenicity in endometrial carcinoma cells (26). Lu et al (27) also reported that miR-505 was downregulated in human hepatoma tissues and cell lines. Importantly, miR-505 upregulation suppressed proliferation, invasion and epithelial-mesenchymal transition in hepatoma cells, via HMGB1 targeting. However, the exact role of miR-505 in osteosarcoma remains unclear. We demonstrated that miR-505 showed the largest decrease in osteosarcoma samples as validated by qRT-PCR. The clinical significance and biological functions of miR-505 in osteosarcoma were then investigated. As studies have demonstrated that TNM stage and tumor size are predictive prognostic factors for recurrence-free survival in osteosarcoma patients (28,29), we found that miR-505 expression levels were associated
with TNM stage, and metastasis status, but not tumor size in the present study. Nevertheless, we determined the level of miR-505 and explored its clinical value in a small cohort and the conclusion was obtained only in a single center. Future studies would contribute to our understanding of the precise clinical significance, such as diagnostic or prognostic value of miR-505 in patients with osteosarcoma. In addition, in vitro assays suggest that miR-505 inhibited MG63 cell proliferation, migration and invasion. These inhibitory effects of miR-505 on cell malignancy behavior may explain why lower miR-505 levels were closed related with advanced pathological stage.

HMGB1 was originally described as a nuclear non-histone DNA binding protein that functions as a structural co-factor critical for proper transcriptional regulation in somatic cells (30). It is passively released by necrotic cells or actively secreted by immune and cancer cells (31,32). Elevated HMGB1 expression is associated with unlimited replicative potential, evasion of programmed cell death, angiopoiesis, tissue invasion and metastasis (33,34). Jube et al (32) revealed that serum HMGB1 levels in malignant mesothelioma patients are higher than those obtained for healthy individuals. In addition, HMGB1 induces migration and proliferation of malignant mesothelioma cells; after treatment with monoclonal antibodies against HMGB1 or its receptor, motility, survival and anchorage-independent growth of HMGB1-secreting malignant mesothelioma cells are reduced. What is more, autophagy activation and HMGB1 release are considered key events underpinning colon carcinoma cell-elicited leukocyte attraction (35). In this study, we determined the levels of HMGB1 in osteosarcoma tissues and HMGB1 mRNA levels were elevated in osteosarcoma tissues as shown above. A recent study demonstrated that HMGB1 expression is associated with clinical prognosis in osteosarcoma. Patients with high HMGB1 expression showed increased tumor size, high TNM stage and nuclear grade, with HMGB1 expression considered an independent predictor of poor prognosis (36). Notably, HMGB1 is considered an active cytokine that regulates the bone microenvironment (15,37). In 2012, Huang et al (38) found that HMGB1 is upregulated during chemotherapy, regulating autophagy during chemotherapy in osteosarcoma cells. HMGB1 suppression increases sensitivity to chemotherapy. Conversely, HMGB1 overexpression increases resistance to chemotherapy in vitro. These findings confirmed that HMGB1 is an important regulator of autophagy-mediated cell survival (39). We further explored the relationship between HMGB1 and miR-505 in the present study. Indeed, Guo et al (40) proposed HMGB1 as a direct target of miR-22 in osteosarcoma, with miR-22 downregulating HMGB1-induced autophagy in osteosarcoma cells. HMGB1 was also reported to be involved in cell growth promotion in neuroblastoma by modulating PTEN expression, via miR-221/222 oncogenic clusters (41). Next, we confirmed that HMGB1 is a direct target of miR-505 in osteosarcoma cell lines, which was consistent with results revealed by Lu et al (27). The above data indicated that HMGB1 downregulation is likely mediated by miR-505 through its binding to the 3′UTR of HMGB1 mRNA, and help better understand the role of HMGB1 in osteosarcoma. However, how HMGB1 exerts its suppressor effects on osteosarcoma cells still needs to be further elucidated.

Overall, the present study demonstrated that miR-505 downregulation is associated with poor clinical prognosis in patients with osteosarcoma; indeed, miR-505 inhibits osteosarcoma cell proliferation, migration and invasion by targeting HMGB1. These findings identified a novel tumor suppressive role for the miR-505/HMGB1 interaction in osteosarcoma.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Ottaviani G and Jaffe N: The etiology of osteosarcoma. Cancer Treat Res 152: 15-32, 2009.
3. Kager L, Zoubek A, Pöttschger U, Kastner U, Flege S, Kempf-Bliellack B, Branscheid D, Krotz R, Salzer-Kuntschik M, Winkelmann W, et al: Cooperative German-Austrian-Swiss Osteosarcoma Study Group: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21: 2011-2018, 2003.
4. Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A and Bacci G: High grade osteosarcoma of the extremities metastatic to the lung: Long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol 19: 193-199, 2010.
5. Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 3: 83-92, 2011.
6. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144, 2006.
7. Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X and Wang L: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol 180: 2440-2451, 2012.
8. Cui SQ and Wang H: MicroRNA-144 inhibits the proliferation, apoptosis, invasion, and migration of osteosarcoma cell line F5M2. Tumour Biol 36: 6949-6958, 2015.
9. Won KY, Kim YW, Kim HS, Lee SK, Jung WY and Park YK: MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma. Hum Pathol 44: 1648-1655, 2013.
10. Huang G, Nishimoto K, Zhou Z, Hughes D and Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72: 908-916, 2012.
11. Liu Y, Xu J, Jiang M, Ni L, Chen Y and Ling Y: Association between functional PSMD10 Rs111638916 variant regulated by miR-505 and gastric cancer risk in a Chinese population. Cell Physiol Biochem 37: 1010-1017, 2015.
12. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calataudy D, Nielsen SE, Yilmaz M, Holländer NH, et al: MicroRNA biomarkers in whole blood for detection of pancreatic cancer. Lab Invest 92: 1239-1252, 2012.
13. Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, Kimura O, Ueno Y, Nakayama K and Shimosegawa T: Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One 8: e66086, 2013.
14. Erlandsdsson Harris H and Andersson U: Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34: 1503-1512, 2004.
15. Charoonpatrapong K, Shah R, Robling AG, Alvarez M, Clapp DW, Chen S, Kopp RP, Pavalko FM, Yu J and Bidwell JP: HMGB1 expression and release by bone cells. J Cell Physiol 207: 480-490, 2006.
16. Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140, 2010.
17. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, et al: Children's Oncology Group: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 26: 633-638, 2008.
18. Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Pici2 F, Fagioli F, Casali PG, et al: A phase II trial of sorafenib in relapsed and unrespectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group Study. Ann Oncol 23: 508-516, 2012.
19. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE and Link MP: Pediatric Oncology Group: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma. Pediatric Oncology Group Study POG-8651. J Clin Oncol 21: 1574-1580, 2003.

20. Nugent M: microRNA and Bone Cancer. Adv Exp Med Biol 889: 201-230, 2015.

21. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, et al: MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19: 1123-1130, 2011.

22. Zhao H, Li M, Li L, Yang L, Lan G and Zhang Y: MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS One 8: e83571, 2013.

23. Zhao J, Chen F, Zhou Q, Pan W, Wang X, Xu J, Ni L and Yang H: Aberrant expression of microRNA-99a and its target gene mTOR associated with malignant progression and poor prognosis in patients with osteosarcoma. Onco Targets Ther 9: 1589-1597, 2016.

24. Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, Horii R, Fukuoka Y, Kato T, Kosaka N, et al: An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer 10: 135, 2011.

25. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.

26. Chen S, Sun KX, Liu BL, Zong ZH and Zhao Y: MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer 15: 1, 2016.

27. Lu L, Qiu C, Li D, Bai G, Liang J and Yang Q: MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1. Life Sci 157: 12-18, 2016.

28. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD and Meyer WH: Metastatic osteosarcoma. Cancer 106: 403-412, 2006.

29. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntzsch M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.

30. Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, Zhang Y, Zhu Y, Chen L and Chen B: The association of HMGB1 gene with the prognosis of HCC. PLoS One 9: e89097, 2014.

31. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.

32. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M and Yang H: Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 72: 3290-3301, 2012.

33. Xia Q, Xu J, Chen H, Gao Y, Gong F, Hu L and Yang L: Association between an elevated level of HMGB1 and non-small-cell lung cancer: A meta-analysis and literature review. Onco Targets Ther 9: 3917-3923, 2016.

34. Ito I, Fukazawa J and Yoshida M: Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 282: 16336-16344, 2007.

35. Cottone L, Capobianco A, Gualteroni C, Perrotta C, Bianchi ME, Rovere-Querini P and Manfredi AA: 5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells. Int J Cancer 136: 1381-1389, 2015.

36. He J, Zhang P, Li Q, Zhou D and Liu P: Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma. Oncol Lett 11: 293-298, 2016.

37. Yang J, Shah R, Robling AG, Templeton E, Yang H, Tracey KJ and Bidwell JP: HMGB1 is a bone-active cytokine. J Cell Physiol 214: 730-739, 2008.

38. Huang H, Ji N, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72: 230-238, 2012.

39. Huang J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 8: 275-277, 2012.

40. Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. Tumour Biol 35: 7025-7034, 2014.

41. Mari E, Zicari A, Fico F, Massimi I, Martina L and Mardente S: Action of HMGB1 on miR-221/222 cluster in neuroblastoma cell lines. Oncol Lett 12: 2133-2138, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.